Clinical characteristics correlation between solute carrier family 7 member 11 gene SLC7A11 and liver cancer

Abstract

Objective To determine the expression level of SLC7A11 gene (solute carrier family 7 member 11) in liver cancer and its adjacent tissues, and to understand the relationship between SLC7A11 gene and the clinical characteristics of liver cancer patients.

Methods The expression level of SLC7A11 gene in 102 liver cancer tissues and their adjacent tissues was determined by semi-quantitative PCR and real-time PCR, and the relationship between SLC7A11 gene and age, sex, tumor size, HBV infection, lymph node metastasis, survival time and histological grade of liver cancer patients was analyzed.

Results Semi-quantitative PCR of SLC7A11 gene in 85.0% (17/20) liver cancer tissues was significantly up-regulated compared with that in paracancerous tissues. Real-time PCR was used to detect SLC7A11 mRNA expression in 102 liver cancer and paracancerous tissues, and SLC7A11 mRNA expression was significantly up-regulated in 72.5% (74/102) liver cancer tissues ( P<0.01). The average survival time of the SLC7A11 mRNA high expression group (64 cases) was 16 months, the average survival time of the low expression group was 22 months, and the survival time of the SLC7A11 mRNA high expression group was shorter ( P<0.01). SLC7A11 mRNA expression was significantly up-regulated in liver cancer patients with tumors larger than 3 cm, SLC7A11 gene expression level was positively correlated with tumor size ( P<0.05), but not with age, sex, HBV infection, lymph node metastasis or histological grade (all P>0.05).

Conclusion SLC7A11 expression is up-regulated in hepatocellular carcinoma, which affects tumor proliferation and survival of patients, suggesting that SLC7A11 plays an important role in the occurrence and development of hepatocellular carcinoma.

Abstract

摘要： 目的 明确溶质载体家族 7 成员 11 基因 ( SLC7A11) 在肝癌及癌旁组织中的表达水平, 了解 SLC7A11 基因与 肝癌患者临床特征的关系。 方法 收集 102 例肝癌患者肝癌组织及其癌旁组织, 通过半定量 PCR、Real-time PCR 测 定 SLC7A11 基因在组织中的表达水平, 分析该基因与肝癌患者年龄、性别、肿瘤大小、HBV 感染、淋巴结转移、生存期 及组织学分级的关系。 结果 随机挑选 20 对肝癌和癌旁组织进行半定量 PCR, SLC7A11 基因在 85.0% (17/20) 的肝癌 组织较癌旁组织中 mRNA 的表达水平明显上调。Real-time PCR 检测 102 例肝癌和癌旁组织中 SLC7A11 mRNA 表达 水平, 72.5% (74/102) 肝癌组织中 SLC7A11 基因表达水平明显上调 ( P<0.01)。在 64 例肝癌患者中 SLC7A11 mRNA 高 表达组的平均生存期为 16 个月, 低表达组的平均生存期为 22 个月, SLC7A11 mRNA高表达组生存期较短 ( P<0.01)。 SLC7A11 基因表达水平与肿瘤大小成正相关, 肿瘤大于 3 cm 的肝癌患者 SLC7A11 基因的表达水平明显上调 ( P<0.05)。 SLC7A11 基因表达水平与患者的年龄、性别、HBV 感染、淋巴结转移与否及组织学分级无关 ( P>0.05)。 结论 SLC7A11 基因在肝癌组织中表达上调, 影响着肿瘤的增生及患者的生存期, 提示 SLC7A11 基因在肝细胞癌发 生发展中起着重要的作用。